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Summary
QUESTIONS UNDER STUDY: The study objective was
to evaluate the impact of the amount of contrast medium
used for transcatheter aortic valve implantation (TAVI) on
short-term outcome. Patients undergoing TAVI are exposed
to repeat contrast medium application both for preproced-
ural screening and during the TAVI procedure itself.
Whether the amount of contrast media is associated with
worse outcome is unclear.
METHODS: A total of 257 patients were included (median
age 82.7 years) and divided into two groups with preserved
and reduced kidney function (glomerular filtration rate <60
ml/min/1.73 m2), respectively. Total volume of contrast
media administered during and within 5 days prior to TAVI
was analysed. A combined early safety endpoint at 30 days
was evaluated.
RESULTS: The early safety endpoint was reached by 31
patients and acute kidney injury occurred in 22 patients.
The median total volume of contrast media administered
was 144 ml (interquartile range 81–225 ml). The amount
of contrast did not independently predict the early safety
endpoint in the overall population (odds ratio [OR] 0.93,
95% confidence interval [CI] 0.56 to 1.53, p = 0.774) and
in subgroups with preserved and reduced kidney function.
Change in creatinine was an independent strong predictor
of the early safety endpoint in the overall population (OR
18.13, 95% CI 4.70 to 69.99, p <0.001), as well as in sub-
groups with preserved and reduced kidney function. The
amount of contrast did not predict a change in creatinine
within 72 hours following TAVI (r = 0.02, 95% CI –0.02 to
0.07, p = 0.368).
CONCLUSION: Decreased kidney function after TAVI in-
fluences outcome. When rather small amounts of contrast
media are used for screening and the TAVI procedure itself,
the amount of contrast media seems not to be an independ-
ent predictor of outcome, further suggesting that decreased
kidney function after TAVI is multifactorial.
Key words: TAVI; contrast media; short-term outcome;
early safety outcome
Introduction
Transcatheter aortic valve implantation (TAVI) has become
an accepted percutaneous procedure for the treatment of
advanced aortic valve disease [1]. Patients undergoing
TAVI are usually older and suffer from a number of co-
morbidities. The mean age range of patients undergoing
TAVI in high-volume registries has been reported to be
between 81 and 84 years old, and the prevalence of co-
morbidities such as chronic obstructive pulmonary disease
(COPD), coronary and peripheral artery disease, as well
as chronic kidney disease (CKD), arterial hypertension and
diabetes is high [2–6]. CKD is one of the most frequently
encountered comorbidities, with a prevalence ranging from
20% to 60% in large studies [7–9]. In most centres, pre-
procedural screening includes – besides echocardiography
– investigations necessitating application of contrast media
(coronary angiography, aortic root angiography, peripheral
angiography, computed tomography). This is followed by
repeat contrast media application during the TAVI proced-
ure itself. Repeat contrast media applications potentially
expose this vulnerable population to an increased risk of
acute kidney injury (AKI). AKI following TAVI is asso-
ciated with significant morbidity and in-hospital mortality
[10] and concomitant CKD increases the incidence of kid-
ney disorders after TAVI up to 30% [11].
The volume of contrast media is considered a major risk
factor associated with AKI in patients undergoing percu-
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taneous coronary intervention (PCI) [12]. Usually systemic
and kidney perfusion change only marginally after PCI,
but haemodynamics are dramatically changed immediately
after TAVI, thereby per se improving kidney perfusion.
However, data concerning the effect of contrast media on
kidney function following TAVI are conflicting [13–16].
While Madershahian et al. reported a possible association
between the extensive use of contrast media during TAVI
and the incidence of contrast-induced nephropathy and
mortality in patients with impaired kidney function [13], a
large multicentre Italian study could not confirm this [14].
The fact that many patients receive additional contrast me-
dia shortly prior to TAVI during computed tomography
and/or angiography has been neglected in previous studies
and not been taken into account in the evaluation of AKI
and short-term outcome.
Thus, the aim of the present study was to evaluate the im-
pact on short-term outcome of the total amount of contrast
media administered shortly prior to and during the TAVI
procedure, as well as the association between contrast me-
dia and kidney function deterioration following TAVI.
Methods
Patient population, screening process and TAVI
procedure
Between April 2012 and June 2014, 257 consecutive pa-
tients undergoing TAVI for severe native aortic valve sten-
osis at the University Heart Centre Zurich were prospect-
ively included in a nationwide registry (Swiss TAVI re-
gistry). Eligibility for TAVI was based on the consensus
of the heart team. Baseline characteristics, procedural and
follow-up data from each patient were entered in the re-
gistry. Each patient signed an informed consent for data
collection and analysis. The registry was approved by the
local ethics committee.
Each patient underwent transthoracic echocardiography
prior to TAVI. Transoesophageal echocardiography has not
been performed routinely. Multi-detector computed tomo-
graphy (CT) to accurately assess the aortic valvular com-
plex for exact prosthesis sizing and to assess vascular ac-
cess site was performed in most patients prior to TAVI. A
bolus of 80–130 ml iodinated contrast media (Iomeprol,
Bracco, Italy) was injected via an antecubital vein. Before
intervention, left or both left and right heart catheterisation
to evaluate coronary and aortic anatomy as well as haemo-
dynamic status was performed in most patients. The time
interval between preprocedural CT, angiography and TAVI
was variable, depending on the urgency of valve replace-
ment. Iopromide (Bayer HealthCare Pharmaceuticals, Ger-
many) was used as contrast medium for both coronary an-
giography and the TAVI procedure.
The default access for TAVI was transfemoral, as was local
anaesthesia. Transaxillary, transapical, or direct aortic ac-
cess was used as alternative access route in cases where
peripheral arterial disease was limiting. Valve implantation
was performed under rapid pacing (for balloon-expandable
valves) or fast pacing (for self-expanding valves).
Standard blood samples for haematology and serum chem-
istry were taken 1 day prior to TAVI and daily thereafter up
to 72 hours after the procedure. Further blood samples were
drawn, depending on the treating physician’s decision. To
prevent contrast-induced AKI, nonuniform protocols, de-
pending on the treating physician’s preference, were ap-
plied in patients with pre-existing impaired kidney func-
tion. Usually, patients received periprocedural hydration
with intravenous normal saline (100 ml/h) starting at least
12 hours prior to and ending 24 hours after TAVI. Intra-
venous n-acetylcysteine was additionally administered at
a dose of 1 200 mg 12 hours before and after TAVI. In
patients with diabetes, metformin was stopped 1 day pri-
or to the intervention and reinstituted after the proced-
ure, depending on kidney function. Contrast-sparing ap-
proaches to minimise the risk of contrast-induced nephro-
pathy are routine measures and were chosen in all patients
with CKD, if possible [17].
Follow-up
Clinical follow-up was performed at 30 days and 12
months, and yearly thereafter either at our institution or
by a local cardiologist. Telephone interviews were used
to complete follow-up. In the case of events, medical re-
cords were reviewed and all events were independently ad-
judicated by a clinical event committee. All events were
defined according to the Valve Academic Research Con-
sortium (VARC)-2 consensus document criteria [18].
Transthoracic echocardiography was performed before in-
tervention, before hospital discharge, at 30 days and 12
months, and yearly thereafter.
Kidney function and contrast media
Baseline kidney function in the form of glomerular filtra-
tion rate (GFR) was determined in each patient based on
the last preprocedural serum creatinine value and the Modi-
fication of Diet in Renal Disease (MDRD) equation [19].
Patients with preserved kidney function at baseline (GFR
≥60 ml/min/1.73 m2) were compared with patients with
reduced kidney function (GFR <60 ml/min/1.73 m2). Pa-
tients on chronic haemodialysis before intervention were
excluded from the analysis (n = 6, 2.3%).
To evaluate the impact of contrast media, all iodinated con-
trast media administered during and within 5 days prior to
TAVI (CT, angiography, PCI) were included in the analys-
is.
Endpoints
The primary endpoint was the VARC-2 early safety end-
point [18], comprising all-cause mortality, all stroke, life-
threatening bleeding, AKI stage 2 or 3, coronary artery
obstruction requiring intervention, major vascular complic-
ation and valve-related dysfunction requiring repeat pro-
cedure (balloon aortic valvuloplasty, surgical aortic valve
replacement, TAVI) up to 30 days.
AKI was defined as a reduction in kidney function within
48 hours following TAVI according to the VARC-2 criteria
[18]: increase in serum creatinine to ≥150% or an increase
of ≥26.4 mmol/l (stage 1); increase in serum creatinine
to 200–299% (stage 2); increase in serum creatinine to
≥300% or an increase in serum creatinine of ≥354 mmol/l
with an acute increase of at least 44 mmol/l or the new in-
stallation of dialysis after TAVI (stage 3).
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Statistical analysis
Continuous variables were expressed as median ± in-
terquartile range (IQR) or mean ± standard deviation, de-
pending on variable distribution, and categorical variables
as numbers and percentages. Comparisons between groups
of patients with preserved and reduced kidney function and
between groups split according to the occurrence of the
early safety endpoint were performed with Mann-Whitney
U test, t test or χ2 test, as appropriate. Firstly, the impact
of the total amount of contrast media on the early safety
endpoint was analysed with a multivariate logistic regres-
sion analysis with adjustment for the total contrast me-
dia volume administered during and within 5 days prior to
TAVI and the Society of Thoracic Surgeons (STS) score
[20]. Secondly, the impact of the change of creatinine with-
in 72 hours following TAVI on the early safety endpoint
was analysed with a multivariate logistic regression ana-
lysis, adjusted for the change of creatinine within 72 hours
after TAVI and the STS score. Finally, the association
between the total amount of contrast media and the change
of creatinine was studied. A multivariate linear regression
model was performed with adjustment for the total amount
of contrast media administered during and within 5 days
prior to TAVI and the STS score to evaluate their impact on
the change of creatinine within 72 hours following TAVI.
Change in creatinine was defined as any change in creat-
inine within 72 hours following TAVI, thus including in-
creased, decreased or unchanged creatinine. As STS score
includes comorbidities such as hypertension, diabetes, pri-
or coronary or peripheral artery disease, prior stroke and
lung disease, this integrated score has been included into
the multivariate model instead of each single risk factor.
The amount of contrast was log transformed to correct for
non-normal distribution. Subgroup analyses have been per-
formed for groups of patients with preserved and reduced
kidney function. Results of logistic regression analysis are
reported as odds ratio (OR) and 95% confidence inter-
val (CI). Correlation is reported as correlation coefficient r
and 95% CI. A p-value <0.05 was considered statistically
significant. All statistical analyses were performed using
a commercially available software package (STATA 12.1,
StataCorp. 4905 Lakeway Drive, College Station, Texas
77845 USA and SPSS Statistics, Version 22, IBM, Chica-
go, IL, USA).
Results
A total of 257 patients were included in the study. Baseline
characteristics are described in tables 1a and 1b. Almost
half of the patients had preserved kidney function (GFR
≥60 ml/min/1.73 m2) at baseline (122 patients [47.5%]),
whereas reduced kidney function (GFR <60 ml/min/1.73
m2) was present in 135 patients (52.5%). Overall, CT and
cardiac catheterisation were performed in 218 (84.8%) and
237 (92.2%) patients, respectively, prior to TAVI.
However, in only 91 (35.4%) and 57 (22.2%) patients, re-
spectively, CT and cardiac catheterisation were performed
within the critical 5-day period prior to TAVI. Four patients
additionally underwent PCI within 5 days prior to TAVI.
The following devices were used for implantation:
CoreValve (Medtronic Inc., Minneapolis, MN, USA, 108
patients, 42%), Edwards Sapien (Edwards Life science,
Irvine, CA, USA, 141 patients, 54.9%), Symetis Acurate
(Symetis ACURATE TA, Symetis Inc., Ecublens, VD,
Switzerland, three patients, 1.2%), St. Jude Medical Portico
(St. Jude Medical, St. Paul, MN, USA, three patients,
1.2%), Direct Flow Medical (Direct Flow Medical Inc.,
Santa Rosa, CA, USA, two patients, 0.8%).
The median amount of contrast used was 80 ml (IQR
40–130 ml) for CT and 84 ml (IQR 60–104 ml) for an-
giography. Overall, the median amount of contrast media
administered during TAVI was 99 ml (IQR 65–147 ml).
Median contrast volume during TAVI in patients with pre-
served versus reduced kidney function was 100 ml (IQR
70–157 ml) versus 88 ml (IQR 60–130 ml, p = 0.035).
Overall, the median total amount of contrast media used
in each patient within the 5-day period was 144 ml (IQR
81–225 ml), with 150 ml (IQR 88–251 ml) in the preserved
kidney function group versus 135 ml (IQR 77–207 ml) in
the reduced kidney function group (p = 0.120).
Early safety endpoint
The early safety endpoint occurred in 31 patients (12.1%;
19 patients [15.6%] in the group with preserved kidney
function, and 12 [8.9%] in the group with reduced kidney
function, p = 0.298). An overview on the events is presen-
ted in table 2.
The amount of contrast administered was not an independ-
ent predictor of the early safety endpoint (table 3), both in
the overall population (OR 0.93, 95% CI 0.56 to 1.53, p =
0.774) and in subgroups with preserved (OR 1.73, 95% CI
0.66 to 4.53, p = 0.266) and reduced kidney function (OR
0.75, 95% CI 0.42 to 1.35, p = 0.340), without evidence for
effect modification (p for interaction = 0.19).
On the other hand, the change in creatinine from baseline
up to 72 hours following TAVI was an independent and
strong predictor of the early safety endpoint (OR 18.13,
95% CI 4.70 to 69.99, p <0.001; table 4). In subgroup ana-
lyses, this creatinine change remained independently asso-
ciated with the early safety endpoint in groups with pre-
served (OR 17.48, 95% CI 2.86 to 106.92, p = 0.002)
and reduced kidney function (OR 25.75, 95% CI 2.86 to
231.92, p = 0.004), without evidence for effect modifica-
tion (p for interaction = 0.46).
Association between amount of
contrast media administered and
change in kidney function
AKI occurred in 9 patients (7.4%) with preserved kidney
function at baseline and in 13 patients (9.6%) with reduced
kidney function (p = 0.519). A small, but statistically
nonsignificant difference was found in the amount of con-
trast media administered to patients who experienced AKI
(159 ml, IQR 80–216 ml) compared with patients without
AKI (142 ml, IQR 83–226 ml, p = 0.798).
Median amount of contrast administered in patients with
postimplant decline in kidney function was higher (154 ml,
IQR 97–236 ml) than in patients with improved kidney
function (139 ml, IQR 77–207 ml). However, the differen-
ce was not statistically significant (p = 0.213). No associ-
ation between the amount of contrast media administered
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during and within 5 days prior to TAVI and a change of
creatinine within 72 hours following TAVI was found (r =
0.02, 95%CI –0.02 to 0.07, p = 0.368; table 5, fig. 1). Fur-
thermore, no such association was found in either subgroup
(subgroup with preserved kidney function [r = 0.06, 95%
CI –0.01 to 0.13, p = 0.112] and reduced kidney function
[r = –0.01, 95% CI –0.07 to 0.05, p = 0.698]). Again, there
was no evidence for effect modification (p for interaction =
0.14).
Bleeding complications
Bleeding complications occurred significantly more often
in patients with reduced kidney function (19 patients
[14.1%]) compared with patients with preserved kidney
function (5 patients [4.1%], p = 0.009). No significant dif-
ference was found for life-threatening bleeding (p = 0.390),
whereas nonlife-threatening bleeding occurred signific-
antly more frequently in patients with reduced kidney func-
tion (p = 0.006).
Discussion
This was a retrospective cohort study analysing the impact
of contrast media used for screening and the TAVI proced-
ure itself on short-term outcome. No association between
the amount of contrast media and the short-term outcome
30 days after TAVI was found, in subgroups with preserved
and reduced kidney function. Surprisingly, the amount of
contrast media was not associated with a change in creatin-
ine shortly after TAVI. However, change in creatinine was
associated with worse short-term outcome.
While operator experience [21], patient selection and ad-
vances in technology [22] lead to a decrease in the incid-
ence of early safety events following TAVI, occurrence of
Table 1a: Patient characteristics according to the early safety endpoint.
Overall population
(n = 257)
No event*
(n = 226)
Event*
(n = 31)
p-value
Age (years), median (IQR) 82.7 (78.4–87.3) 82.6 (78.4–87.1) 84.9 (77.8–88.0) 0.55
Males, n (%) 127 (49.4) 110 (48.7) 17 (54.8) 0.52
Body mass index (kg/m2), median (IQR) 25.9 (23.4–29.1) 25.85 (23.4–29.1) 26.1 (24.1, 29.8) 0.62
Diabetes, n (%) 63 (24.5) 54 (23.9) 9 (29.0) 0.53
Hypertension, n (%) 191 (74.3) 170 (75.2) 21 (67.7) 0.37
Dyslipidaemia, n (%) 79 (30.7) 68 (30.1) 11 (35.5) 0.54
COPD, n (%) 47 (18.3) 43 (19.0) 4 (12.9) 0.41
Prior CVI, n (%) 30 (11.7) 26 (11.5) 4 (12.9) 0.82
Prior PCI, n (%) 56 (21.8) 50 (22.1) 6 (19.4) 0.73
Prior MI, n (%) 28 (10.9) 26 (11.5) 2 (6.5) 0.40
Known CAD, n (%) 124 (48.2) 110 (48.7) 14 (45.2) 0.71
Known PAD, n (%) 37 (14.4) 29 (12.8) 8 (25.8) 0.05
Prior cardiovascular surgery, n (%) 34 (13.2) 31 (13.7) 3 (9.7) 0.53
Kidney function
GFR >90 ml/min/1.73 m2, n (%) 26 (10.1) 23 (10.2) 3 (9.7) 0.82
GFR 60–89 ml/min/1.73 m2, n (%) 96 (37.4) 87 (38.5) 9 (29.0)
GFR 45–59 ml/min/1.73 m2, n (%) 70 (27.2) 62 (27.4) 8 (25.8)
GFR 30–44 ml/min/1.73 m2, n (%) 37 (14.4) 31 (13.7) 6 (19.4)
GFR 15–29 ml/min/1.73 m2, n (%) 22 (8.6) 18 (8.0) 4 (12.9)
GFR <15 ml/min/1.73 m2, n (%) 6 (2.3) 5 (2.2) 1 (3.2)
Dialysis, n (%) 6 (2.3) 5 (2.2) 1 (3.2) 0.73
Creatinine at baseline (µmol/l), median (IQR) 97 (81–126) 97 (81–123) 111 (84–137) 0.26
GFR at baseline (ml/min/1.73 m2), mean ± SD 59.8 ± 24.1 60.2 ± 23.8 56.6 ± 25.9 0.43
STS score, median (IQR) 4.62 (3.1–7.67) 4.59 (2.9–7.0) 5.89 (3.2–9.34) 0.08
Aortic valve area at baseline (cm2), median (IQR) 0.70 (0.60–0.90) 0.70 (0.60–0.90) 0.70 (0.60–0.90) 0.98
Mean gradient at baseline (mm Hg), mean ± SD 43 ± 16 43 ± 16 44 ± 16 0.68
LVEF at baseline (%), median (IQR) 58.5 (47–65) 59 (47–65) 56 (45–65) 0.78
Contrast volume
Contrast for CT (ml), median (range) 80 (40–130) 80 (40–130) 80 (60–80) 0.16
Contrast for angiography (ml), median (IQR) 98 (75–144) 101 (75–145) 90 (60–130) 0.21
Contrast for TAVI (ml), median (IQR) 99 (65–145) 95 (65–145) 104 (60–160) 0.67
Total contrast during and within 5 days prior to TAVI (ml), median (IQR) 144 (81–225) 139.5 (84–220) 159 (60–270) 0.77
Devices
Medtronic CoreValve, n (%) 108 (42.0) 93 (41.2) 15 (48.4) 0.63
Edwards Sapien, n (%) 141 (54.9) 126 (55.8) 15 (48.4)
Symetis Acurate, n (%) 3 (1.2) 2 (0.9) 1 (3.2)
SJM Portico, n (%) 3 (1.2) 3 (1.3) 0 (0.0)
Direct Flow Medical, n (%) 2 (0.8) 2 (0.9) 0 (0.0)
* Early safety endpoint at 30 days
CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CT = computed tomography; CVI = cerebrovascular insult; GFR = glomerular filtration
rate; IQR = interquartile range; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PAD = peripheral artery disease; PCI = percutaneous coronary
intervention; SD = standard deviation; STS = Society of Thoracic Surgeons; TAVI = transcatheter aortic valve implantation.
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AKI is still a relevant problem. In our study the incidence
of AKI was 9%. This is in line with other studies, where
the incidence of AKI was reported to be between 8–28%
and was associated with a higher 30-day mortality [11, 15,
23–29]. Therefore, any measures to reduce AKI incidence
are important.
Table 1b: Patient characteristics according to kidney function at baseline.
GFR
<60 ml/min/1.73 m2
(n = 135)
GFR
≥60 ml/min/1.73 m2
(n = 122)
p-value
Age (years), median (IQR) 82.4 (79.4–88.4) 82.0 (76.8–85.3) 0.01
Males, n (%) 54 (40.0) 73 (59.8) <0.01
Body mass index (kg/m2), median (IQR) 26.5 (23.9–29.8) 25.7 (23.4–28.1) 0.47
Diabetes, n (%) 41 (30.4) 22 (18) 0.02
Hypertension, n (%) 105 (77.8) 86 (70.5) 0.18
Dyslipidaemia, n (%) 43 (31.9) 36 (29.5) 0.68
COPD, n (%) 23 (17.0) 24 (19.7) 0.59
Prior CVI, n (%) 12 (8.9) 18 (14.8) 0.14
Prior PCI, n (%) 34 (25.2) 22 (18.0) 0.17
Prior MI, n (%) 17 (12.6) 11 (9.0) 0.36
Known CAD, n (%) 71 (52.6) 53 (43.4) 0.14
Known PAD, n (%) 26 (19.3) 11 (9.0) 0.02
Prior cardiovascular surgery, n (%) 22 (16.3) 12 (9.8) 0.13
Absolute change in creatinine (µmol/l), median (IQR)* –4.5 (–18 to 11.8) –3.0 (–9.5 to 4.0) 0.24
Absolute change in GFR (ml/min/1.73 m2), median (IQR)* +1.7 (–4.0 to 9.3) +3.7 (–4.7 to 12.3) 0.43
GFR at baseline (ml/min/1.73 m2), median (IQR) 44.9 (32.0–52.3) 75.0 (67.7–87.4) <0.01
STS score, median (IQR) 6.50 (4.20–10.70) 3.6 (2.5–5.0) <0.01
Aortic valve area at baseline (cm2), median (IQR) 0.70 (0.60–0.90) 0.72 (0.60–0.90) 0.26
Mean gradient at baseline (mm Hg), mean ± SD 43 ± 16 43 ± 16 0.97
LVEF at baseline (%), median (IQR) 57 (45–65) 59 (50–65) 0.49
Contrast volume
Contrast for CT (ml), median (range) 80 (80–130) 80 (40–130) 0.02
Contrast for angiography (ml), median (IQR) 95 (70–138) 103 (75–154) 0.24
Contrast for TAVI (ml), median (IQR) 88 (60–130) 100 (70–157) 0.04
Total contrast during and within 5 days prior to TAVI (ml), median (IQR) 135.0 (77–207) 150 (88–251) 0.10
Devices
Medtronic CoreValve, n (%) 62 (45.9) 46 (73.7) 0.35
Edwards Sapien, n (%) 69 (51.1) 72 (59.0)
Symetis Acurate, n (%) 2 (1.5) 1 (0.8)
SJM Portico, n (%) 2 (1.5) 1 (0.8)
Direct Flow Medical, n (%) 0 (0.0) 2 (1.6)
* Minus means a decrease in creatinine or GFR, plus means an increase in creatinine or GFR
CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CT = computed tomography; CVI = cerebrovascular insult; GFR = glomerular filtration
rate; IQR = interquartile range; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PAD = peripheral artery disease; PCI; percutaneous coronary
intervention; SD = standard deviation; STS = Society of Thoracic Surgeons; TAVI = transcatheter aortic valve implantation.
Table 2: Events at 30 days.
Event All
n = 257
GFR ≥60 ml/min/1.73 m2
n = 122
GFR <60 ml/min/1.73 m2
n = 135
p-value
Early safety endpoint 31 (12.1) 19 (15.6) 12 (8.9) 0.30
All-cause mortality 9 (3.5) 3 (2.5) 6 (4.4) 0.39
Cardiovascular mortality 8 (3.1) 3 (2.5) 5 (3.7) 0.57
Noncardiovascular mortality 1 (0.4) 0 1 (0.7) 0.34
Myocardial infarction 0 0 0
Stroke/TIA 8 (3.1) 4 (3.3) 4 (3.0) 0.88
Bleeding 24 (9.3) 5 (4.1) 19 (14.1) 0.01
Life-threatening 9 (3.5) 3 (2.5) 6 (4.4) 0.39
Nonlife-threatening 15 (5.8) 2 (1.6) 13 (9.6) 0.01
Acute kidney injury 22 (8.6) 9 (7.4) 13 (9.6) 0.52
Stage 1 18 (7.0) 9 (7.4) 9 (6.7) 0.82
Stage 2 or 3 4 (1.6) 0 4 (3.0) 0.06
Conduction disturbances and arrhythmias 34 (13.2) 17 (13.9) 17 (12.6) 0.75
Valve-related dysfunction requiring repeat
procedure
2 (0.8) 1 (0.8) 1 (0.7) 0.94
Values are expressed as n (%)
GFR = glomerular filtration rate; TIA = transient ischaemic attack.
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Interestingly, the amount of contrast administered in our
study was relatively low and was not an independent pre-
dictor of the early safety endpoint (median 99 ml, IQR
65–147 ml). Our findings are in line with the findings of
Bagur et al., where a similarly low amount of contrast was
used (mean 97 ± 57 ml) [25]. This indicates that AKI in
TAVI patients is most likely multifactorial. Several differ-
ent reasons for a decline of kidney function following TAVI
have been reported [25], for example, major bleeding re-
quiring red blood cell transfusion has been shown to in-
crease the risk of AKI following TAVI [11, 25]. In the
present study, 14% of all patients received red blood cell
transfusion. Thus, efforts to reduce bleeding complications
are important to improve the outcome following TAVI –
this is particularly true for patients in atrial fibrillation who
are at high-risk for major bleeding complications [30]. Left
Figure 1
Association between the total amount of contrast media (in ml)
administered during and within 5 days prior to TAVI and absolute
changes in creatinine (in μmol/l) within 72 hours following TAVI in
each patient according to preinterventional kidney function
(preserved kidney function: GFR ≥60 ml/min/1.73 m2 versus
reduced kidney function: GFR <60 ml/min/1.73 m2).
atrial appendage occlusion may offer an attractive treat-
ment option in these patients [31].
Secondly, short periods of severe hypotension during TAVI
have been suggested to be risk factors for AKI, although
Bagur et al. did not find an association between the number
of rapid pacing runs and the occurrence of AKI [25].
Thirdly, most patients with severe aortic stenosis undergo-
ing TAVI suffer from diffuse atherosclerosis and manipula-
tion with catheters in the aorta and on the aortic valve may
expose patients to the risk of arteriosclerotic microembol-
ism with temporary deterioration of kidney function.
In clinical practice we try to save contrast in every patient,
but particularly in patients with decreased renal function.
We recently showed that TAVI with minimal amounts of
contrast can be safely performed [17]. Therefore, the find-
ings of the present study came as some surprise. Although
the amount of contrast for TAVI can be reduced to as little
as 8 ml [17], the total amount of contrast used in this
study was rather low (144 ml, including screening CT and
screening angiograms performed within 5 days prior to the
procedure). Furthermore, only a few patients in our cohort
had severely decreased kidney function (GFR <30 ml/min/
1.73 m2), precluding a separate subgroup analysis for these
patients.
The fact that the amount of contrast media was not associ-
ated with a change in creatinine within 72 hours following
TAVI was surprising, as contrast media are well-known risk
factors of renal impairment. Contrast-induced nephropathy
affects predominantly patients with chronic kidney disease
[32]. The prevalence of moderate to severe kidney failure
was rather low in the present study, which might in part ex-
plain our findings. Contrast-sparing approaches and peri-
interventional hydration therapy were used and may further
have influenced our results. Furthermore, treatment of the
severe aortic stenosis itself leads to an increased cardiac
output and reduced venous congestion, thereby improving
renal perfusion and thus glomerular filtration rate immedi-
ately after the intervention [33].
Other factors are also associated with worsening kidney
function, such as the use of nonfemoral approaches (8.9%
Table 3: Impact of contrast media as a predictor of events (n for events = 31) at multivariable regression.
All patients GFR ≥60 ml/min/1.73 m2 GFR <60 ml/min/1.73 m2
OR 95% CI OR 95% CI OR 95% CI
Log total contrast media 0.93 0.56 to 1.53 1.73 0.66 to 4.53 0.75 0.42 to 1.35
STS score 1.03 0.98 to 1.09 0.98 0.85 to 1.14 1.03 0.97 to 1.10
CI = confidence interval; GFR = glomerular filtration rate; OR = odds ratio; STS = Society of Thoracic Surgeons
Table 4: Impact of change of creatinine as a predictor of events (n for events = 31) at multivariable regression.
All patients GFR ≥60 ml/min/1.73 m2 GFR <60 ml/min/1.73 m2
OR 95% CI OR 95% CI OR 95% CI
Change of creatinine within
72 hours
18.13 4.70 to 69.99 17.48 2.86 to 106.92 25.75 2.86 to 231.92
STS score 1.04 0.99 to 1.10 0.98 0.85 to 1.15 1.05 0.99 to 1.12
CI = confidence interval; GFR = glomerular filtration rate; OR = odds ratio; STS = Society of Thoracic Surgeons
Table 5: Impact of contrast media as a predictor of change of creatinine within 72 hours after transcatheter aortic valve implantation.
All patients GFR ≥60 ml/min/1.73 m2 GFR <60 ml/min/1.73 m2
r 95% CI r 95% CI r 95% CI
Log total contrast media 0.02 –0.02 to 0.07 0.06 –0.01 to 0.13 –0.01 –0.07 to 0.05
STS score 0.00 –0.01 to 0.00 0.00 –0.01 to 0.01 0.00 –0.01 to 0.00
CI = confidence interval; GFR = glomerular filtration rate; STS: Society of Thoracic Surgeons
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in our study population) [34], the occurrence of major vas-
cular complications (2.3% in our study population) [35] or
moderate and severe postimplant aortic regurgitation (2.3%
in our population) [36]. Whether the amount of contrast
applied during TAVI procedures differently influences out-
come in patients with or without one of the above men-
tioned risk factors needs to be evaluated in further studies.
In the present study, patients with reduced kidney function
experienced significantly more bleeding complications
compared with patients with preserved kidney function,
which is in line with previous data [37]. This finding
should especially be taken into account in patients with at-
rial fibrillation, as with simultaneous left atrial appendage
occlusion anticoagulation can be stopped and thus bleeding
complications can further be reduced. However, simultan-
eous left atrial appendage occlusion requires additional
contrast media application, thus further underlining the ef-
forts to reduce the amount of contrast media in this popula-
tion.
Taken together, despite our findings, we still consider ef-
forts to reduce the amount of contrast before or during the
procedure beneficial, particularly in patients with reduced
kidney function. Areas to reduce the amount of contrast
in such patients are the screening CT, which can either be
omitted [17], replaced by (3D-)echocardiography [38], or
reduced to a minimal-contrast selective CT of the peripher-
al vessels [39]. A screening coronary angiogram can be
omitted, as can a peripheral angiogram [17]. If it is felt
that a screening angiogram and a CT need to be performed,
the procedures should be staged in order to allow the kid-
neys to recover and to minimise the temporal contrast ex-
posure. An important phase in which to reduce the amount
of contrast is intraprocedurally, with techniques previously
described.
If measures to minimise the risk of AKI are taken, we
should still opt for an as safe procedure as possible, in-
cluding selective administration of contrast media where
needed. Therefore, the findings presented here should en-
courage us to use contrast media, but to use them wisely
and selectively, always keeping in mind that an optimal
TAVI result should be the primary goal of each procedure.
Limitations
This study has several limitations. The association between
the amount of contrast media and changes in creatinine has
been evaluated only within 72 hours following TAVI. Thus,
we cannot exclude the possibility that longer follow-up of
kidney function may be necessary to find an association
between the amount of contrast media and a change in cre-
atinine.
The time interval between preprocedural evaluations with
contrast media administration (CT, angiography) and the
TAVI procedure was variable. This might have introduced a
bias in the analysis of the impact of the amount of contrast
media on the kidney function, as it could be expected that
patients with known CKD might have had a longer time in-
terval between procedures to reduce the risk of AKI. Con-
sequently, the cumulative dose of contrast media was lower
in patients with CKD in the present study. Furthermore, pa-
tients with CKD were routinely treated with hydration and
n-acetylcysteine to reduce further the potential risk of AKI.
The smaller amount of contrast media administered in the
group of patients with reduced kidney function compared
with the group with preserved kidney function might have
introduced a bias in the results of the multivariate analysis.
However, as our data reflect daily clinical routine, these
results might be of more practical importance. Prospective
studies with administration of the same amount of contrast
in patients with preserved and reduced kidney function
seem not to be feasible because of ethical concerns.
Finally, the sample size of 257 patients might have influen-
ced the results of the present study. Considering the num-
ber of TAVI procedures performed per year, the sample size
of our study represents the experience of a high-volume
centre in a time-period with increasing acceptance of TAVI
as an alternative to open aortic valve surgery in selected pa-
tients. Multicentre studies to increase the sample size are
needed to assess further the impact of contrast media on
short-term outcome, and in particular to evaluate the high-
risk patient group with moderately to severely reduced kid-
ney function.
Conclusion
AKI following TAVI has a major impact on outcome. The
occurrence of AKI is most likely multifactorial. Contrast-
sparing approaches are probably beneficial particularly in
patients with severely decreased kidney function, but if
rather small amounts of contrast media are used for screen-
ing and the TAVI procedure itself, the amount of contrast
seems not to be an independent predictor of outcome in an
overall TAVI-cohort.
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Figures (large format)
Figure 1
Association between the total amount of contrast media (in ml) administered during and within 5 days prior to TAVI and absolute changes in
creatinine (in μmol/l) within 72 hours following TAVI in each patient according to preinterventional kidney function (preserved kidney function:
GFR ≥60 ml/min/1.73 m2 versus reduced kidney function: GFR <60 ml/min/1.73 m2).
Original article Swiss Med Wkly. 2015;145:w14238
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 9 of 9
